173 related articles for article (PubMed ID: 38359967)
1. Epigenetic therapeutic strategies in pancreatic cancer.
Orlacchio A; Muzyka S; Gonda TA
Int Rev Cell Mol Biol; 2024; 383():1-40. PubMed ID: 38359967
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of PDAC subtype heterogeneity and therapy response.
Espinet E; Klein L; Puré E; Singh SK
Trends Cancer; 2022 Dec; 8(12):1060-1071. PubMed ID: 36117109
[TBL] [Abstract][Full Text] [Related]
3. Role of epigenetics in pancreatic ductal adenocarcinoma.
Pandey S; Gupta VK; Lavania SP
Epigenomics; 2023 Jan; 15(2):89-110. PubMed ID: 36647796
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
Ciernikova S; Earl J; García Bermejo ML; Stevurkova V; Carrato A; Smolkova B
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521716
[TBL] [Abstract][Full Text] [Related]
6. PHLPP2 is a novel biomarker and epigenetic target for the treatment of vitamin C in pancreatic cancer.
Chen L; Song H; Luo Z; Cui H; Zheng W; Liu Y; Li W; Luo F; Liu J
Int J Oncol; 2020 May; 56(5):1294-1303. PubMed ID: 32319585
[TBL] [Abstract][Full Text] [Related]
7. Missing links - epigenetic regulators of the pancreatic cancer-associated inflammation.
Werba G; Gonda TA
Clin Sci (Lond); 2021 May; 135(10):1289-1293. PubMed ID: 34047338
[TBL] [Abstract][Full Text] [Related]
8. Regulation of pancreatic cancer therapy resistance by chemokines.
Gautam SK; Basu S; Aithal A; Dwivedi NV; Gulati M; Jain M
Semin Cancer Biol; 2022 Nov; 86(Pt 2):69-80. PubMed ID: 36064086
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
Hessmann E; Johnsen SA; Siveke JT; Ellenrieder V
Gut; 2017 Jan; 66(1):168-179. PubMed ID: 27811314
[TBL] [Abstract][Full Text] [Related]
11. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
[TBL] [Abstract][Full Text] [Related]
12. The biological underpinnings of therapeutic resistance in pancreatic cancer.
Beatty GL; Werba G; Lyssiotis CA; Simeone DM
Genes Dev; 2021 Jul; 35(13-14):940-962. PubMed ID: 34117095
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
Tarannum M; Vivero-Escoto JL
Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
[TBL] [Abstract][Full Text] [Related]
14. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
15. Precision Medicine and Pancreatic Cancer.
George B
Surg Oncol Clin N Am; 2021 Oct; 30(4):693-708. PubMed ID: 34511190
[TBL] [Abstract][Full Text] [Related]
16. Drivers of Gene Expression Dysregulation in Pancreatic Cancer.
Venkat S; Alahmari AA; Feigin ME
Trends Cancer; 2021 Jul; 7(7):594-605. PubMed ID: 33618999
[TBL] [Abstract][Full Text] [Related]
17. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
[TBL] [Abstract][Full Text] [Related]
18. High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.
Curia MC; Fantini F; Lattanzio R; Tavano F; Di Mola F; Piantelli M; Battista P; Di Sebastiano P; Cama A
BMC Cancer; 2019 May; 19(1):452. PubMed ID: 31088413
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.
Du J; Gu J; Li J
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32677676
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]